Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Prefrontal cortical dopamine (DA) regulates various executive cognitive functions, including attention and working memory. Efforts to enhance prefrontal-related cognition, which have focused on catecholaminergic stimulant drugs, have been unsatisfactory. Recently, the demonstration that a functional polymorphism in the catecholamine-O-methyltransferase (COMT) gene impacts prefrontal cognition raises the possibility of a novel pharmacological approach for the treatment of prefrontal lobe executive dysfunction. To explore in a proof of concept study the effects of tolcapone, a CNS penetrant specific COMT inhibitor, we performed a randomized, double blind, placebo controlled, and crossover design of this drug in normal subjects stratified by COMT (val158met) genotype. COMT enzyme activity was determined in peripheral blood. Forty-seven normal volunteers with no family history of psychiatric disorders underwent neuropsychological testing and 34 of those subjects underwent physiological measurement of prefrontal information processing assessed by blood oxygen level-dependent functional magnetic resonance imaging (fMRI). We found significant drug effects on measures of executive function and verbal episodic memory and a significant drug by genotype interaction on the latter, such that individuals with val/val genotypes improved, whereas individuals with met/met genotypes worsened on tolcapone. fMRI revealed a significant tolcapone-induced improvement in the efficiency of information processing in prefrontal cortex during a working memory test. This study demonstrates enhancement of prefrontal cortical function in normal human subjects with a nonstimulant drug having COMT inhibitory activity. Our results are consistent with data from animal studies and from computational models of the effects of selective enhancement of DA signaling in the prefrontal cortex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increasing dopamine activity in the mPFC improved set-shifting in humans (Apud et al 2007).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Apud et al 2007
In the citing paper
“For example, increasing DA levels in individuals who have high baseline DA levels impairs cognitive performance, (perhaps pushing them over the peak of the inverted U curve) whereas improvements are noted in individuals with lower baseline levels (pushing them closer to the apex of the curve) (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007; Cools, Frank et al. 2009).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
In the citing paper
“Furthermore, increasing DA levels interacts with the COMT val158met SNP consistent with the putative inverted U model with met individuals demonstrating diminished cortical efficiency during tasks of cognitive control and val individuals demonstrating improvements (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
Citations
Cites
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381 · cited 6×
“This genetic effect has been demonstrated in humans for performance on a variety of cognitive tests, such as working memory and executive function (Egan et al, 2001; Ho et al, 2005) as well as prefrontal physiology as assessed by functional magnetic resonance imaging (fMRI) (Egan et al, 2001;…”
BackgroundMethodInfluentialSelf-citationChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675 · cited 3×
“COMT val158met (rs4680 G to A) genotyping was determined using Taqman 50-exonuclease allelic discrimination assay (Applied Biosystems, Foster City, CA) as described elsewhere (Chen et al, 2004).”
BackgroundMethodSelf-citationThe principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 2×
“There are also reports that COMT genotype affects function on declarative memory tests referable to processing in temporal lobe structures implicated in long-term memory (de Frias et al, 2004) Converging evidence from electrophysiological studies in experimental animals indicates that DA focuses and stabilizes prefron…”
BackgroundMendelian Proportions in a Mixed Population
Hardy, G. H. (1908) · Science · doi:10.1126/science.28.706.49 · Cited by 1,339
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · cited 2×
“0 h after administration of tolcapone and maximum inhibition of COMT activity in red blood cells is achieved between 1 and 4 h following administration of the drug (Jorga et al, 1999; Jorga, 1998; Mannisto and Kaakkola, 1999).”
BackgroundInfluentialMattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 9×
“In fact, the effects of amphetamine on prefrontal efficiency measured with fMRI (Mattay et al, 2003) were more noticeable in val/val individuals, a group with putatively higher COMT activity in the frontal cortex and, hence, relatively lower DLFPC synaptic DA concentrations.”
BackgroundMethodInfluentialSelf-citationGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 4×
“…release or metabolism, studies of COMT knock-out mice and of COMT inhibitors in rodents indicate that COMT has little impact on norepinephrine flux in prefrontal cortex, perhaps because of the abundance of functional norepinephrine transporters (Gogos et al, 1998; Tunbridge et al, 2004).”
BackgroundResultInfluentialAuditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 819 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal cortical contributions to working memory: evidence from event-related fMRI studies
D'Esposito, M., Postle, B. R., & Rypma, B. (2000) · Experimental Brain Research · doi:10.1007/s002210000395 · Cited by 794 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741 · cited 1×
“This drug by genotype effect is consistent with relatively lower prefrontal cortical DA signaling in these subjects and presumed benefit of enhanced prefrontal DA in this context (Mattay et al, 2003; Weinberger et al, 2001).”
BackgroundSelf-citation
Research works printed but not linked: 3
- McNair D, Lorr M (1981). ITS Manual for the Profile of Mood States. Multi-health System, Inc.: San Diego, CA.
- Weinberg W (1908). ber den Nachweis der Vererbung beim Menschen. Jahresh Ver Vaterl Naturk Württemb 64: 368–382.
- Zurcher G, Dingemanse J, Da Prada M (1991). Ro-40-7592, A Potent Inhibitor of Extracerebral and Brain Catechol-O-methyltransferase: Preclinical and Clinical Findings. John Libbey SRL: Rome.
Cited by
Items 201–246 of 246
Xavier, J., Bastos, C. R., Camerini, L., Amaral, P. B., Jansen, K., Souza, L. D. D. M., da Silva, R. A., Pinheiro, R. T., Lara, D. R., & Ghisleni, G. (2022) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10186 · Cited by 2
DeVito, E. E., & Sofuoglu, M. (2022) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-022-00251-2 · Cited by 3
The Genome, Genes and Brain – Tailored Drugs
Adler, L. (2010) · Wiley eBooks · doi:10.1002/9780470749180.ch3 · Cited by 1
Treating the Cognitive Deficits of Schizophrenia
Rogers, B. N., & Gray, D. L. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00123 · Cited by 1
Tan, H. Y., & Weinberger, D. R. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0013 · Cited by 1
Self-citationUsing Genetics to Improve Addiction Treatment Outcomes
Allenby, C. E., & Falcone, M. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0106-9 · Cited by 1
New drug targets in psychiatry: Neurobiological considerations in the genomics era
Harrison, P. J., Mould, A. W., & Tunbridge, E. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104763 · Cited by 1
“by Val158Met genotype have demonstrated interactive effects between them, whereby COMT inhibition enhances cognitive performance in Val158 homozygotes but has no effect or even impairs performance in Met158 homozygotes (Farrell et al., 2012; Giakoumaki et al., 2008; Apud et al., 2007).”
BackgroundPharmacological Treatment for Cognitive Disorders of Neurovascular Origin
Flanagan, S. R., & Gordon, W. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-70715-0_18 · Cited by 1
Chapter 3.8 The multiple roles of dopaminergic neurotransmission in episodic memory
Schott, B. H., & Düzel, E. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00221-x · Cited by 3
Current awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.898 · Cited by 1
Visual working memory in health and disease
Gorgoraptis, N. (2013) · UCL Discovery (University College London)
Catechol-O-methyltransferase and pain in rodents and humans
Kambur, O. (2013) · Työväentutkimus Vuosikirja · Cited by 1
Behavioral impulsivity and hallucinations : insights from Parkinson's disease
Ashourian, P. (2011) · DSpace@MIT (Massachusetts Institute of Technology)
Konzeption und Grundlagen einer funktionalen Psycho pharmako therapie
Gründer, G., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_1
Entwicklungen in der Neurogenetik am Beispiel der Schizophrenie
Meyer‐Lindenberg, A. (2010) · Psychiatrie und Psychotherapie up2date · doi:10.1055/s-0029-1223481
BIOMARKERS AND PUBLIC–PRIVATE PARTNERSHIPS
Littman, B. H., & Krishna, R. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.010
Psychology and biology of memory
Meyer‐Lindenberg, A., & Goldberg, T. E. (2012) · doi:10.1093/med/9780199696758.003.0032
Self-citation10.2 Neuropharmacological Profiles of Antipsychotic Drugs
Roth, B. L., & Rogan, S. C. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0037
The Genetics of Cognition in Schizophrenia: Combining Mouse and Human Studies
Scheggia, D., & Papaleo, F. (2017) · Wiley eBooks · doi:10.1002/9781118540770.ch6
Monoaminergic Regulation of Cognitive Control in Laboratory Animals
Jentsch, J. D., Groman, S. M., James, A. S., & Seu, E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1268-8_3 · Cited by 1
“shifting in humans (Apud et al. 2007) and in rats (Tunbridge et al.”
BackgroundStumpenhorst, K. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-6gy6qkoeg
The effect of psychological and biological factors on financial choices
Wang, D. (2018) · ePrints Soton (University of Southampton)
Martens, M. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-r52yj5qwa · Cited by 2
Sulfonation and methylation in silico : Modelling studies on SULT1A3 and COMT
Sipilä, J. (2020) · Helda - University of Helsinki Institutional Repository
Zmigrod, L., & Robbins, T. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2wqgm
Mihaylova, A., Doncheva, N., Zlatanova, H., Delev, D. P., & Kostadinov, I. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.513
Leeder, J. S., & Gaedigk, A. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718025936.793479689
Funktionale Pesychopharmakotherapie
Gründer, G., & Heinz, A. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_52
Liu, L., Qian, L., Yang, H., Ye, Q., Xu, Z., Liu, Y., Wang, Z., Wu, W., & Liu, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3206277/v1
Schacht, J. P., Kubicki, M., & Anton, R. F. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15227
HR/MS-based lipidome analysis of rat brain modulated by tolcapone
Rebouta, J., Dória, M. L., Coelho, A., Fonseca, M. M., Castilla‐Fernández, G., Pires, N. M., Vieira‐Coelho, M. A., & Loureiro, A. I. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.115971
Neurochemistry of executive functions
Lenzoni, S., Guruprasath, G., Zhunussova, A., Leiman, M., Ludwig, M., Penalba‐Sánchez, L., & Hämmerer, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-820480-1.00065-6
Winters, D. E., & Schacht, J. P. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.06.003 · Cited by 1
Padmanabhan, A. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · Figshare · doi:10.6084/m9.figshare.19759925
Prefrontal cortex mechanisms of the novel cognitive enhancer d-govadine
Nesbit, M. O. (2023) · cIRcle (University of British Columbia) · doi:10.14288/1.0436918 · Cited by 2
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · Figshare · doi:10.6084/m9.figshare.19759919
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · Figshare · doi:10.6084/m9.figshare.19759928
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · Figshare · doi:10.6084/m9.figshare.19759916
Margetts, G., Kleidonas, S., Zaibi, N. S., Zaibi, M. S., & Edwards, K. D. (2022) · Figshare · doi:10.6084/m9.figshare.19759922
Qian, L., Xu, Z., Ye, Q., Jiang, T., Wu, W., Liu, X., & Liu, L. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100232
Gorgievski, V. (2013) · theses.fr (ABES) · doi:10.70675/7e4ade13za71az4368zbeafzd9e42fabc738
The therapeutic potential of COMT inhibition: cognition and beyond
Tunbridge, E. M., Carr, G. V., & Weinberger, D. R. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03824-9
Self-citationKokhan, V. S., & Shamakina, I. Y. (2026) · Психофармакология и биологическая наркология · doi:10.17816/phbn716259
Reward and Anxiety: From Rodent Post-Traumatic Stress to Human Psychosocial Stress
Frías, C. F., & Sarai, N. (2012)
Neurogenetic Risk Mechanisms of Schizophrenia: An Imaging Genetics Approach
Meyer‐Lindenberg, A. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0913-8_11
“In a proof of concept study, Apud et al. (2007) used a COMT-inhibiting drug, tolcapone, to demonstrate genotype-dependent effects on prefrontal function and cognitive performance.”
Background
Metadata
- Authors
- Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., Goldberg, T. E., & Weinberger, D. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Weinberger, Daniel R
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-10-25
- Volume
- 32
- Issue
- 5
- Pages
- 1011-1020
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2123236884
- Cited by
- 242
- References
- 39
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 9 · 2023: 4 · 2022: 19 · 2021: 9 · 2020: 12 · 2019: 4 · 2018: 7 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 6 · 2013: 25 · 2012: 18
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- tolcapone, COMT inhibition, COMT Val158Met polymorphism, prefrontal cortex, executive function, working memory, verbal episodic memory, dopamine signaling
- MeSH terms
- Tolcapone, Adult, Benzophenones, Brain Mapping, Catechol O-Methyltransferase, Cognition, Double-Blind Method, Enzyme Inhibitors, Female, Genotype, Humans, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Neuropsychological Tests, Nitrophenols, Placebos, Reference Values, Treatment Outcome, Prefrontal Cortex, Cross-Over Studies, Amino Acid Substitution, Catechol O-Methyltransferase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.